Physiomics Ventures into Rheumatoid Arthritis with New UK Contract

PUBLISHED: May 09 2025 @ 03:11 | Comments (0) | More info about Fiona Craig

Physiomics plc (LSE:PYC) has entered the rheumatoid arthritis field by securing a contract with a UK-based client to apply its population Pharmacokinetic modelling techniques to Phase 1 clinical data for a small molecule aimed at treating the condition. The £67,500 contract, expected to be completed within three months, represents Physiomics’ first foray into rheumatoid arthritis and a strategic expansion into new therapeutic areas. The agreement also includes a Master Service Agreement for future collaborations, showcasing the company’s growing client base and increasing expertise in supporting advanced-stage drug development.

Despite this strategic expansion, Physiomics faces significant financial instability, with declining revenues and negative profit margins impacting its outlook. Technical indicators suggest a bearish sentiment, and while recent developments indicate potential pathways for growth, financial concerns and valuation challenges remain substantial.

About Physiomics plc

Physiomics plc specializes in mathematical modelling, biostatistics, and data science, with a focus on optimizing drug development processes and personalized medicine solutions. The company collaborates with biotech and pharmaceutical companies, applying its expertise in Modelling & Simulation, Bioinformatics, and Data Science to enhance the development of new therapeutics. Physiomics has supported over 100 commercial projects, working with high-profile clients such as Merck KGaA, Astellas, and Bicycle Therapeutics.

Average Daily Trading Volume: 7,097,380
Technical Sentiment: Sell
Market Capitalization: £1.46 million

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.